Ladies and gentlemen, welcome to the nine months 2026 financial results conference call and live webcast. I am Mathilde, the Chorus Call operator. I would like to remind you that all participants will be in listen-only mode, and the conference is being recorded. The presentation will be followed by a question-and-answer session. You can register for questions at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it is my pleasure to hand over to Jan Keppeler, Head of Investor Relations. Please go ahead.
Thank you, Mathilde. Good afternoon or good morning to everyone joining us today for our earnings call, on what I assume is a very busy earnings day for many of you. With me today is Marcus Wolfinger, CEO of Stratec, and our CFO, Tanja Bücherl. Please be aware that this conference is being webcast live, and you can download the presentation either from the webcast or from our website. As always, before we start, I want to draw your attention to our safe harbor statement, which is on page two of this presentation. With that, I am happy to hand over to Marcus.
Yeah, thanks, Jan, and a very warm welcome from my side as well. This is not the AI Marcus or a deepfake. I just have a minor head cold, so sorry for this voice. We were intending to give you an overview of what happened over the first nine months, followed by the details of the Diatron transaction. Then we will give you a financial review of the nine-month figures as well as the third quarter, followed by an outlook, and at the end, I hope we will be able to answer your questions. Let me start with the key messages of the first nine months and the third quarter. First, growth in our core system line. Our molecular and immunoassays, blood bank systems, complex sample prep grew by double digits in the first nine months.
These are the platforms and foundations and instruments our strategy is built on, performing all very well. Certainly, the technological spread and depth is much wider, particularly when looking into the details of consumables or our Development and Services and lead pipeline. Second, profitability. Adjusted EBIT grew by 36% in the third quarter, and the adjusted EBIT margin reached 11.3%, an improvement of 370 basis points. That figure is year-on-year. Cash generation is also much stronger as to the comps. Operating cash flow in the first nine months was EUR 39.4 million compared with a slightly negative figure a year ago. This year's cash development was very much driven by the very revenue-heavy Q4 in the year 2025, where a lot of the accounts receivable swapped into 2026, giving us an excellent cash flow start into 2026.
And then third, our pipeline, as we are seeing a noticeable increase in customer evaluating Stratec platforms, and the demand very much for product lifecycle management projects remain extremely high. We are also making good progress in moving new developments into early-stage series production. However, filling the early-stage development pipeline remains key. Finally, visibility for the first quarter has improved. However, there is still some way to go. I will get back on that in our outlook. Just one note, all figures on this slide still include the Diatron business. Let me now touch base on the Diatron transaction. On the last day of October, we signed an agreement. I think it was actually October 30. We signed an agreement to sell Diatron to a consortium of investors from India.
The scope covers 100% of Diatron in Hungary, including the U.S. business and Indian subsidiaries, and all Diatron products in hematology and clin chem. Stratec molecular and immunoassays business stays with Stratec, as does, and that is important, as does part of our Hungarian manufacturing footprint. Financially, we receive a fixed purchase price of EUR 10 million plus potential earnout payments. For 2026, we expect the sold business to contribute around EUR 20 million in sales, but an adjusted EBIT margin of around minus EUR 10 million. Those EUR 20 million I have just mentioned compare to approximately EUR 30 million under the initial guidance given early this year. So we are giving up revenue, but we are removing a drag on earnings. The rationale is straightforward. We are focusing on our core business.
Fully integrated automated systems for high-end central labs and point of need is our core market in the U.S., Europe, and selected parts of Asia. Over the past years, Diatron's markets have moved in different direction, and the new owners know those markets very well. Actually, the stakeholders have built and grown the India business for companies like Roche and GE. This Diatron measure gives Stratec the basis for a structural better margin profile and is not a clean break. With Diatron, under the new owner, we already have certain collaborations in place and are working on future product cooperations regarding ongoing new collaborations. With that overview, I would like to hand over to Tanja. She will give us the financial details.
Thanks, Marcus. Also from my side, good afternoon, good morning, and a warm welcome to our today's call. There is actually one important statement that I want to make before turning into the numbers. As Marcus had mentioned, unless stated otherwise on the slides, the figures that I will guide you through now are still including the Diatron business. The outlook pages that you will see later refer to the continued operations only, means without the Diatron business. So, this distinction is actually very important or essential when comparing the reported results with the forward-looking targets. So, let us get started. The reported revenue amounted to EUR 165 million in the first nine months, compared with EUR 176 million in the prior year period. This leads actually to a decline of 5% at constant currency and 6.1% on the reported base.
As explained earlier by Marcus, the revenue development was mixed across our different business areas. We saw the positive momentum in our molecular and immunoassays system, while actually the overall revenue performance was significantly affected by lower service parts and consumables, the hematology revenue from our Diatron business, and lower Development and Services revenue. When you look into the line below, despite the lower revenue level, the adjusted EBIT actually increased to EUR 13.7 million from roughly EUR 13 million in the prior year period. The adjusted EBIT margin therefore improved to 8.3% compared to the 7.3% in the prior year. Let me emphasize, the quarterly development was even stronger actually. In the third quarter, the adjusted EBIT increased by 37% year-on-year base, and the adjusted EBIT margin we've overachieved actually the overall target from our old guidance of 11.3%.
This represents an improvement of 370 basis points compared with the third quarter of the prior year. Let me allow maybe one additional remark on the quarterly development. We managed pretty good to be only slightly below the strong Q2 that we showed during this year. Another positive element of our financial performance, as you see down below, is the free cash flow. The free cash flow increased to EUR 30.6 million compared with the negative EUR 14.8 million from 2025. I will explain the development of the key figures actually a bit more on the next slide. First, let me start with our adjustments. Again, it is important to distinguish between the reported and our adjusted performance. The reported figures include, especially in this quarter, substantial non-cash valuation effects related to the Diatron signature on the 30th of last month.
This valuation effect amounts roughly to EUR 44 million and were therefore adjusted in the reconciliation to the operating performance figures. In addition, you know, those are the standard adjustments with the PPA amortization and other effects like expenses for advisors, reorganization costs, and so on. Looking to the right side of this slide, the reported net result was negative, again, primarily reflected by the Diatron-related valuation effect. On the other hand, the adjusted net income amounted to EUR 7.5 million compared with the EUR 7.1 million in 2025. The adjusted earnings per share increased from EUR 0.62- EUR 0.58. The same distinction actually applies to the earnings per share that you see on that slide. The reported earnings per share were negative at EUR 3.13, reflecting the transaction-related valuation effects again, while adjusted earnings per share has actually indicated an underlying earning performance of the period.
The overall financial picture is therefore actually characterized by three elements, if I would need to summarize it: the lower revenue, the improved adjusted operation profitability, and the significant improvement in cash generation. Let's have a look a bit more into the sales development. As I and Marcus have mentioned earlier, the development was mixed across our different business areas. Let me start with the immunoassay and molecular diagnostic business, which has shown a very positive development compared with the prior year period, with a double-digit growth. What I would like to highlight is especially the molecular business development after the post-COVID depression that we have faced in there. This positive performance in our core business was, however, partially offset, especially by the negative development in the Diatron hematology business.
The Diatron hematology business was actually roughly 80% below the prior year level, and this decline was mainly driven by one specific product and should therefore be viewed in the context of the product-specific situation within the Diatron portfolio. It was very important for us also when we are talking about the future after Diatron. Looking into the service parts, they have actually contributed in absolute terms with the highest portion. As you all know, the service parts represent approximately two-thirds of our official reported service parts and consumables revenue, which makes actually development in this area very relevant for our overall revenue performance and also the earnings performance of Stratec. We have mentioned it in the prior calls already.
The decline, especially in the service parts revenue, is mainly attributable to one customer that has undergone a change in ownership structure, and this development is not an effect that we see only in 2026. It actually has already started in the second half year of 2025 and continued into 2026. I think we, as board, as a Stratec group, we are therefore not treating this as a short-term quarterly fluctuation. We have definitely reflected the lower revenue level from this customer in our planning assumptions and have already factored this lower service parts revenue into our fourth quarter outlook. Last but not least, our development in service decline is at approximately 7% compared to the prior year period, but this is mainly related to project timing and shifts of activities into the fourth quarter rather than a fundamental deterioration in our underlying project pipeline.
Let us have a look into our earnings. Our adjusted EBIT and the adjusted EBIT margin of the first nine months. Adjusted EBIT increased by 6.5% year- on- year from EUR 12.8 million to EUR 13.7 million. At the same time, the adjusted EBIT margin improved by 100 basis points from 7.3% to 8.3%. This is actually a positive development, particularly considering the revenue decline over the same period. The improvement in the adjusted EBIT is, it is really showing that our business benefits from efficiency measures, especially on the personal cost side, by roughly EUR 3 million and a supporting product mix are helping us to overcome the revenue decline in our margin. On the other hand, it is the last bullet point on the positive momentums, we need to be also very open and transparent.
The currency effects have supported our earnings generation, but it is very important that we definitely would not attribute the margin development to FX alone in the first nine months. Now coming to the cash flow, free cash flow and net debt actually. The operating cash flow, as you see on the left side of the chart, increased significantly to EUR 39.4 million in the first nine months compared with the negative figure that we are seeing here with EUR 1.4 million in 2025. To understand the quality of this cash flow improvement, it is important to start really with the underlying earnings position. The consolidated net income before the Diatron write-off actually amounted to roughly EUR 3 million compared with EUR 4 million in the prior year period. Means the higher operating cash flow was not mainly driven by the earnings base.
The main driver was actually the development in the working capital. This was the main contributor, and in the working capital, actually the trade receivables are a very important contributor to that development. As you see on the right hand of this slide, trade receivables actually decreased from EUR 56.9 million at year-end 2025 to EUR 38.1 million at the end of September 2026. This is actually a significant improvement in our absolute working capital terms and was the key contributor to the strong operating cash flow. To this positive cash flow contribution, the trade receivables, which amounted in the first nine months of 2026 to roughly EUR 19 million, this reflects especially our very back-end loaded 2025 revenue that Marcus had mentioned.
In the prior period, the trade receivables had actually a negative free cash flow impact of EUR 5.9 million, which is, yeah, reflecting an increase in receivable and therefore a use of cash. The second important working capital effect came from contract assets under IFRS 15. These generated cash inflows of roughly EUR 3 million in the current period compared with a cash outflow of roughly EUR 8 million in 2025.
This reflects just the timing of milestone payments received from customers in relation to the Development and Services projects. In certain cases, customers make milestone payments before their related revenue can be recognized, and the amounts are initially reflected as contract assets and are subsequently released against revenue recognition. This positive momentum also in the contract assets reflects the timing of our customer payments and the revenue recognition. What it does not mean is a change in our accounting policy.
The last two points on that slide, inventories actually were broadly unchanged from a cash flow perspective. Although, when you looked into our balance sheet, the value for inventories decreased from EUR 113 million at year-end 2025 to EUR 95 million at the end of September, but the inventory movements did not represent the main driver on the year-on-year operating cash flow improvement. Also, the trade payables were broadly unchanged, as you can see on that slide. The free cash flow, I think it's also worth to mention closely on that. We see also in the free cash flow this positive momentum mainly driven by the operating cash flow. Looking maybe last but not least in our financing cash flow, the financing activities were negative with EUR 32.3 million in the first nine months. This mainly reflects debt repayments and the dividend payments.
Cash at the end of the period amounted to EUR 21.2 million compared with EUR 23.1 million at year-end 2025. Despite at a lower cash balance, the net debt decreased significantly to EUR 89 million from EUR 112 million at the end of 2025. This is what we actually can see also in our ratios. On the right side of the chart, you see also our leverage, so means the net debt ratio to EBITDA. Maybe one important note on that. Due to the Diatron divestiture, we actually aligned to restate the leverage here, so to not use the original EBITDA, neither we used here the adjusted EBITDA, which is giving us then a leverage of 2.3. With that, I think we are coming to the most important topic of today's call, and I would like to hand over back to Marcus.
Yeah. Thanks, Tanja. Here is our updated guidance for 2026 now for continuing operations only. According to the applicable rules of International Financial Reporting Standards, Diatron is now accounted for as a discontinued operation. For sales, we expect a stable to slightly higher result at constant currency compared to the pro forma 2025 sales of EUR 223.5 million, excluding Diatron. For the adjusted EBIT margin, we now expect about 13%-15%. That reflects the structural improvement on EBIT. Investments intangible, and Tanja mentioned that already, at the lower end, investments on tangible and intangible assets are expected to 5%-7% of sales. As in previous years, and I think we mentioned that, and based on the current order forecast, we expect a strong year-end. Now, getting into the visibility. On the left-hand side, you can see the restated figures without Diatron.
In the first nine months, sales were EUR 151.8 million compared with EUR 157.4 million last year. Adjusted EBIT actually rose from EUR 17.2 million- EUR 20.3 million, and the margin improved from 10.9% to 13.4%. So even with slightly lower sales, we are earning more at a clearly higher margin. On the right is what we need for the fourth quarter to reach the midpoint of our sales guidance, around EUR 76 million. This chart shows how that breaks down. The gray segments are low-risk volumes, mostly already contracted or booked in systems, service parts and consumables, and Development and Services. This makes up the large majority. The red and reddish segments are volumes where we are confident, but timing is less certain, and we are relying on historical patterns. So, two assumptions are very important.
First, we do not assume any recovery in service part sales compared with the nine-month run rate, and show predictability there is way to go. Second, the strong year-end in systems and development shows a high share of binding orders and contracted work. Let me now dive into the focus for, let me say, the rest of 2026, which is probably less important than what's the matter beyond. Finally, our priorities for the rest of this year. Operationally, we will maintain cost and cash discipline throughout the company without doing over-saving. More than ever, the future of the company lies in the talent and dedication of its employees. This is very important for us. Second, as far as things are under our control, we will ensure complete and timely transfer of newly developed systems into series production at the expected quality.
And we are set up to deliver the elevated manufacturing volumes planned for the remainder of this year. Strategically, we will continue to execute our deal pipeline for new development and manufacturing agreements, and even more importantly, push as hard as we can on filling the early-stage development pipeline. This is definitely key and remains paramount. We work to limit the impact of rising input costs on profitability, whether from inflation or geopolitics, de-globalization, exploding lead times, chip prices, RAM shortage, and you name it. Last but not least, we will continue to focus on addressing growing localization requirements, mainly driven by two factors. One is regulatory fragmentation. Like back in the days, it was sufficient to have CE marking and FDA clearance. Now, literally every country has its own regulatory setup, which are actually, from time to time, are standing in contrast to each other.
And certainly, the geopolitical development that particularly a lot of our Asian and U.S. customers are requiring us for local activities, more local activities. With a sharper focus and a strong margin base, we are very well positioned for 2026 and beyond. That gets us to the end of the presentation. Thank you so far, and Tanja and I will be happy to take your questions.
We will now begin the question-and-answer session. Anyone who wishes to ask a question may press star and one on their telephone. You will hear a tone to confirm that you have entered the queue. If you wish to remove yourself from the question queue, you may press star and two. Questioners on the phone are requested to disable the loudspeaker mode and eventually turn off the volume from the webcast while asking a question. Anyone who has a question may press star and one at this time. As a reminder, if you wish to register for a question, please press star and one on your telephone. Ladies and gentlemen, there are no questions at this time. I would now like to turn the conference back over to Jan Keppeler for any closing remarks.
Thanks, Mathilde. This concludes then our today's conference call. Thanks again, everyone, for joining. If you have any follow-up questions, please do not hesitate to contact us or anyone else from the investor relations team. Thank you and goodbye.
Ladies and gentlemen, the conference is now over. Thank you for choosing Chorus Call, and thank you for participating in the conference. You may now disconnect your lines. Goodbye.